EKTAY
PINK Elekta AB Unsponsored ADR Class B$5.13 ↓ -0.09 (-1.82%) Trading Down from the previous close of $5.23, and at the day’s high of $5.13
- YTD change
- -16.02%
- vs 20-day SMA
- -3.03%
- vs 200-day SMA
- -9.22%
Price ranges
Price & Performance
-0.64 (-10.94%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 67.0% away from all-time highs of $15.56
- EKTAY is down 16% since the beginning of the year
- EKTAY is up 3% over the past 12 months
- EKTAY is down 10% over the past 1 month
EKTAY reads not so good: price sits below both the 20- and 200-day averages, the 12-month move is +4.7%.
- Previous minute
- +$0.00
- Last hour
- -$0.17
- Last 5 days
- -2.04%
- vs 8-day SMA
- -0.95%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Elekta AB is a medical technology company, which engages in the provision of clinical solutions for the treatment of cancers and brain disorders. The firm's products and solutions include radiotherapy, stereotactic radiosurgery, oncology informatics, brachytheraphy, neurosurgery, and particle therapy. It operates through the following geographical segments: Americas, EMEA, APAC, and Others. The company was founded by Lars Leksell and Laurent Leksell in 1972 and is headquartered in Stockholm, Sweden.
Competitor comparison
| Ticker | Company | Price | Change |
|---|---|---|---|
| FSNUY | Fresenius SE & Co. KGaA Sponsored ADR | $12.66 | +0.35% |
| SRTOY | Sartorius Stedim Biotech SA Unsponsored ADR | $25.49 | +2.16% |
| FSPKF | Fisher & Paykel Healthcare Corporation Limited | $26.01 | +1.60% |
| HSIC | Henry Schein, Inc. | $83.97 | -1.18% |
| EBOSY | EBOS Group Limited Sponsored ADR | $23.30 | +3.15% |
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.